Supply of meningococcal (Groups A,C,W-135 and Y) oligosaccharide CRM197 (MENEVEO) conjugate vaccine powder and solution for injection vials by Novartis Vaccines and Diagnostics Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to provide a regulatory framework for therapeutic goods in Australia, ensuring their safety, quality, and efficacy. This legislation was introduced to address the need for a comprehensive legal structure to govern the manufacture, supply, and advertising of therapeutic goods, aiming to protect public health and safety. The Therapeutic Goods Act 1989 is administered by the Australian Government Department of Health, with its purpose to establish and maintain a system that ensures therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. This legislative framework enables the regulation of therapeutic goods through various orders and regulations, allowing for effective control and monitoring of these products within the marketplace. On December 7, 2012, the delegate of the Secretary of the Department of Health and Ageing gave consent under sections 14 and 14A of the Therapeutic Goods Act 1989 for the supply of a meningococcal vaccine that did not fully comply with certain labelling requirements stipulated in Therapeutic Goods Order 69, illustrating the Act’s role in balancing public health needs with practical considerations in the therapeutic goods industry.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, including their supply, manufacture, evaluation, and advertising. The Act applies to various entities, including individuals and corporations, who are involved in the supply or manufacture of therapeutic goods. The scope of the Act extends to all therapeutic goods, which include medicines, medical devices, blood and blood components, tissues, and certain other products. The Act's jurisdiction is national, applying across the entire Commonwealth of Australia, including states and territories. However, the Act does not extend to matters that are specifically covered by other federal laws, such as the Quarantine Act 1908. Additionally, certain exclusions and exemptions apply, such as for therapeutic goods that are prescribed by the Poisons Standard, or for research purposes under the National Health and Medical Research Council Act 1992. The Act also allows for the creation of subordinate instruments, such as Therapeutic Goods Orders, which provide further detail on specific aspects of the regulation of therapeutic goods. These Orders can extend or restrict the application of the Act, providing additional controls or exemptions as necessary.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") contains several key provisions relevant to the regulation of therapeutic goods, including specific sections that address the approval and supply of such goods. Section 14 and Section 14A of the Act are particularly pertinent in this context. Section 14 allows the delegate of the Secretary of the Department of Health and Ageing to give consent for the supply of therapeutic goods that do not fully comply with the standards set out in the Therapeutic Goods Orders. Section 14A provides a mechanism for such consent to be given under specific conditions. In this case, on December 7, 2012, the delegate granted consent (under these sections) for the supply of a meningococcal conjugate vaccine (MENVEO) produced by Novartis Vaccines and Diagnostics Pty Ltd, despite it not fully conforming to certain labelling requirements specified in Therapeutic Goods Order 69. The Act imposes specific obligations on both the manufacturer and the delegate in cases where a therapeutic good does not fully conform to the requirements set out in the Therapeutic Goods Orders. For the manufacturer, this involves ensuring that the product meets all necessary standards before it is supplied. In this instance, the vaccine does not have the required active ingredient and sponsor name on the MenCWY vial labels, and lacks the active ingredient on the MenA vial labels. For the delegate, the obligation is to assess the application for consent, taking into account the public health implications and whether the non-conformance poses a significant risk to public health. The delegate must also be satisfied that the benefits of supplying the therapeutic good outweigh any potential risks. Failure to comply with the requirements of the Therapeutic Goods Act or the Therapeutic Goods Orders can lead to significant legal consequences. Under the Act, non-compliance can result in both civil and criminal penalties. Civil penalties can include fines, with the maximum penalty varying depending on the nature and severity of the offence. For example, supplying a therapeutic good that does not comply with the standards can result in fines of up to $1,260,000 for a corporation, as stipulated in Section 42AB of the Act. Criminal penalties can also be imposed, and in the most severe cases, individuals responsible for the non-compliance can face imprisonment. The exact penalties depend on the specific breach and the jurisdiction in which the offence occurs, but the Act provides a framework for enforcing compliance and protecting public health.